Breast cancer statistics, 2019

Carol E DeSantis, Jiemin Ma, Mia M Gaudet, Lisa A Newman, Kimberly D Miller, Ann Goding Sauer, Ahmedin Jemal, Rebecca L Siegel, Carol E DeSantis, Jiemin Ma, Mia M Gaudet, Lisa A Newman, Kimberly D Miller, Ann Goding Sauer, Ahmedin Jemal, Rebecca L Siegel

Abstract

This article is the American Cancer Society's biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5-year period (2012-2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor-positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5-year period (2013-2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016-2017. Declines in breast cancer mortality could be accelerated by expanding access to high-quality prevention, early detection, and treatment services to all women.

Keywords: breast neoplasms; epidemiology; health disparities; incidence; molecular subtype; mortality.

© 2019 American Cancer Society.

References

    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, based on the November 2018 submission. National Cancer Institute, Surveillance Research Program, Surveillance Systems Branch; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. Breast Schema for 1988-2015 Based on AJCC 6th Edition. Accessed August 8, 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Submission (2000-2016) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total U.S., 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2015, for NHIAv2 Origin, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries). NAACCR; 2018.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2016, for Expanded Races, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries). NAACCR; 2018.
    1. Surveillance, Epidemiology, and End Results (SEER) Program (). SEER*Stat Database: Mortality - All COD, Total U.S. (1969-2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released May 2019. Underlying mortality data provided by NCHS ().
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Aggregated With State, Total U.S. (1990-2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment>. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019. Underlying mortality data provided the by National Center for Health Statistics.
    1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. Published online June 11, 2019. doi:10.3322/caac.21565
    1. American College of Surgeons Commission on Cancer. National Cancer Database, 2016 Data Submission. American College of Surgeons Commission on Cancer; 2019.
    1. Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012-2014. Ann Surg Oncol. 2019;26:1604-1612.
    1. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data 2016. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2016.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
    1. Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011;103:1397-1402.
    1. Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Version 8.3.5. National Cancer Institute; 2018.
    1. National Cancer Institute. Joinpoint Regression Program, Version 4.7.0.0. Statistical Research and Applications Branch, National Cancer Institute; 2019.
    1. National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7. Statistical Research and Applications Branch, National Cancer Institute; 2019.
    1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2016. Based on the November 2018 SEER data submission, posted to the SEER website April 2019. Surveillance, Epidemiology, and End Results Program, National Cancer Institute, National Institutes of Health; 2019.
    1. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26:809-815.
    1. Scott LC, Mobley LR, Kuo TM, Il'yasova D. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer. 2019.
    1. Gomez SL, Glaser SL, Horn-Ross PL, et al. Cancer research in Asian American, Native Hawaiian, and Pacific Islander populations: accelerating cancer knowledge by acknowledging and leveraging heterogeneity. Cancer Epidemiol Biomarkers Prev. 2014;23:2202-2205.
    1. Sung H, DeSantis CE, Fedewa SA, Kantelhardt EJ, Jemal A. Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. Cancer. Published online June 13, 2019. doi:10.1002/cncr.32293
    1. Parise C, Caggiano V. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. Cancer Epidemiol. 2014;38:556-562.
    1. Gaudet MM, Gierach GL, Carter BD, et al. Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype. Cancer Res. 2018;78:6011-6021.
    1. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048.
    1. Hines LM, Sedjo RL, Byers T, et al. The interaction between genetic ancestry and breast cancer risk factors among Hispanic women: the Breast Cancer Health Disparities study. Cancer Epidemiol Biomarkers Prev. 2017;26:692-701.
    1. Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. JAMA Surg. 2017;152:485-493.
    1. Huo D, Hu H, Rhie SK, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017;3:1654-1662.
    1. Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst. 1987;79:701-770.
    1. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer. 2011;117:2209-2218.
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
    1. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-1674.
    1. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control. 2010;21:83-90.
    1. DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011;20:733-739.
    1. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27:1214-1222.
    1. DeSantis CE, Ma J, Jemal A. Trends in stage at diagnosis for young breast cancer patients in the United States. Breast Cancer Res Treat. 2019;173:743-747.
    1. John EM, Hines LM, Phipps AI, et al. Reproductive history, breast-feeding and risk of triple negative breast cancer: the Breast Cancer Etiology in Minorities (BEM) study. Int J Cancer. 2018;142:2273-2285.
    1. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: Final Data for 2017. Natl Vital Stat Rep. 2018;67:1-50.
    1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
    1. Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106:dju289.
    1. Daly B, Olopade OI. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015;65:221-238.
    1. Newman LA. Parsing the etiology of breast cancer disparities. J Clin Oncol. 2016;34:1013-1014.
    1. Warnecke RB, Campbell RT, Vijayasiri G, Barrett RE, Rauscher GH. Multilevel examination of health disparity: the role of policy implementation in neighborhood context, in patient resources, and in healthcare facilities on later stage of breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2019;28:59-66.
    1. Molina Y, Silva A, Rauscher GH. Racial/ethnic disparities in time to a breast cancer diagnosis: the mediating effects of health care facility factors. Med Care. 2015;53:872-878.
    1. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9-16.
    1. Albornoz CR, Matros E, Lee CN, et al. Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction. Plast Reconstr Surg. 2015;135:1518-1526.
    1. Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat. 2012;135:893-906.
    1. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682-2690.
    1. Nash R, Goodman M, Lin CC, et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012. JAMA Surg. 2017;152:648-657.
    1. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111-121.
    1. Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25:2241-2248.
    1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
    1. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617-628.
    1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288-300.
    1. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
    1. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20:e175-e186.
    1. Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2:pky062.
    1. Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr. 2014;2014:210-217.
    1. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165-173.
    1. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33:2254-2261.
    1. Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA. Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24:1039-1045.
    1. Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319:154-164.
    1. Costa RLB, Gradishar WJ. Triple-negative breast cancer: current practice and future directions. J Oncol Pract. 2017;13:301-303.
    1. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:619-626.
    1. Sommers BD, Long SK, Baicker K. Changes in mortality after Massachusetts health care reform: a quasi-experimental study. Ann Intern Med. 2014;160:585-593.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
    1. Singh GK, Hiatt RA. Trends and disparities in socioeconomic and behavioural characteristics, life expectancy, and cause-specific mortality of native-born and foreign-born populations in the United States, 1979-2003. Int J Epidemiol. 2006;35:903-919.
    1. Hunt BR, Hurlbert MS. Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005-2014. Cancer Epidemiol. 2016;45:169-173.
    1. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599-1614.
    1. Siu AL; US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:279-296.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir